target
papain
famili
cystein
proteas
one
novel
strategi
develop
chemotherapi
number
diseas
novel
cystein
proteas
inhibitor
deriv
pyridin
repres
pharmacolog
import
class
compound
report
first
time
deriv
initi
design
screen
silico
molecular
dock
studi
papain
explor
possibl
mode
action
molecular
interact
compound
cystein
proteas
papain
found
similar
interact
observ
respect
epoxid
inhibitor
papain
subsequ
compound
synthes
valid
efficaci
wet
lab
experi
character
kinet
compound
show
k
ic
valu
rang
mm
mm
respect
thermodynam
studi
suggest
bind
papain
hydrophob
entrop
driven
inhibitor
also
inhibit
growth
clinic
import
differ
type
gram
posit
gram
neg
bacteria
mic
valu
rang
mgml
base
lipinski
rule
five
also
propos
compound
potent
antibacteri
prodrug
activ
antibacteri
compound
found
imidazo
pyridin
cysteineproteas
inhibitor
cpi
gain
consider
attent
last
coupl
decad
mani
class
compound
current
human
clinic
trial
number
diseas
interest
papain
famili
cystein
proteas
chemotherapeut
target
deriv
recognit
critic
life
cycl
pathogen
mani
microorgan
cystein
proteas
streptococcu
sp
streptopain
staphylococcu
sp
staphopain
plasmodium
falciparum
trypanosoma
cruzi
cruzipain
wide
studi
member
papain
famili
report
link
sever
infect
variou
patholog
condit
caus
microorgan
activ
kallikreinkinin
pathway
could
activ
sixteen
bacteri
proteas
mechan
pathogen
exploit
ensur
suppli
nutrient
site
infect
increas
vascular
permeabl
shown
occur
infect
sever
microbi
speci
includ
pseudomona
serratia
clostridium
candida
bacteroid
porphyromona
staphylococcu
sp
mani
bacteria
secret
sever
nonspecif
proteas
eg
pseudomona
serratia
streptococcu
staphylococcu
bacteroid
sp
potent
metallo
cystein
serin
proteas
broad
rang
activ
critic
role
bacteri
proteas
virul
success
demonstr
elimin
proteaseencod
gene
p
gingivali
recent
describ
cystatin
superfamili
protein
compris
eukaryot
prokaryot
cystein
proteas
inhibitor
human
cystatin
c
rat
cystatin
chicken
cystatin
oryza
cystatin
report
inhibit
replic
certain
virus
bacteria
although
yet
directli
demonstr
effect
due
proteas
inhibitori
capac
cystatin
key
role
cystein
proteas
microbi
infect
coupl
rel
lack
redund
compar
mammalian
system
made
microbi
proteas
attract
target
develop
novel
chemotherapeut
approach
imidazopyridin
ring
system
repres
import
class
compound
theoret
interest
also
pharmacolog
point
view
shown
possess
broad
rang
use
pharmacolog
activ
includ
antigastr
antisecretori
local
anesthet
antivir
antianxieti
antibacteri
antifung
antihelminth
antiprotozo
anticonvuls
gastrointestin
antiulc
zolmidin
anxiolyt
alpidem
hypnot
zolpidem
immunomodulatori
natur
posit
substitu
pyridin
moieti
influenc
pharmacolog
activ
imidazopyridin
heterocycl
structur
form
part
skeleton
natur
alkaloid
neuromuscular
block
agent
revers
inhibitor
h
k
atpas
enzym
potent
antisecretori
activ
known
sed
hypnot
nervou
system
studi
propos
kinet
thermodynam
character
pyridylimidazo
pyridin
deriv
potent
novel
cystein
proteas
inhibitor
also
act
antibacteri
agent
crystal
structur
papain
extract
protein
data
bank
pdb
code
water
molecul
heteroatom
remov
hydrogen
atom
ad
protein
charmm
forcefield
appli
structur
subject
energi
minim
step
use
steepest
descent
method
chemic
structur
synthes
compound
gener
use
chemdraw
subsequ
convert
format
use
corina
seri
dock
experi
carri
design
pyridylimidazo
pyridin
deriv
papain
use
autodock
tool
possibl
cysteineproteas
inhibitori
activ
compound
select
basi
bind
energi
reflect
good
bind
affin
analyz
silico
platform
paramet
molecular
dock
lamarckian
genet
algorithm
combin
genet
algorithm
local
search
pseudosoli
wet
algorithm
employ
grid
box
gener
around
activ
site
papain
make
sure
inhibitor
freeli
rotat
insid
grid
number
dock
run
set
dock
repeat
five
time
end
total
dock
run
check
precis
result
final
obtain
dock
complex
subsequ
visual
use
pymol
work
authent
wet
lab
detail
analysi
silico
platform
design
deriv
filter
lipinski
rule
five
set
criteria
druglik
properti
drug
like
properti
often
use
character
novel
lead
compound
accord
rule
poor
absorpt
expect
mw
log
hydrogen
bond
donor
hydrogen
bond
acceptor
silico
absorpt
distribut
metabol
excret
adm
properti
deriv
also
predict
use
follow
onlin
bioinformat
tool
n
http
wwworganicchemistryorg
n
http
mobylerpbsunivparisdiderotfrcgibinport
py
form
admetox
n
http
securechemsilicocompagessubmitphp
studi
gave
us
idea
exist
possibl
mutagen
tumorigen
properti
synthes
compound
result
obtain
help
us
screen
synthes
compound
usag
potent
lead
base
result
dock
studi
ten
deriv
pyridin
synthes
accord
siddiqui
et
al
name
follow
capac
pyridin
deriv
inhibit
cystein
proteas
test
use
papain
model
enzym
proteolyt
activ
reaction
mixtur
determin
use
bzdlargpna
chromogen
substrat
solut
activ
papain
final
concentr
mm
ad
concentr
solut
differ
deriv
final
concentr
mm
incub
min
substrat
solut
ad
incub
min
reaction
stop
addit
trichlor
acid
tca
acidifi
hcl
absorb
reaction
mixtur
determin
wavelength
nm
micropl
manag
biorad
laboratori
procedur
use
thermodynam
studi
kinet
paramet
substrat
hydrolysi
determin
measur
initi
rate
enzymat
activ
inhibit
constant
k
determin
dixon
method
also
lineweaverburk
equat
k
valu
calcul
doublereciproc
equat
fit
data
comput
softwar
origin
lineweaverburk
plot
use
determin
type
inhibit
kinet
analysi
rate
constant
determin
assay
carri
triplic
averag
valu
consid
throughout
work
temperatur
depend
inhibit
constant
use
determin
thermodynam
paramet
chang
enthalpi
dh
determin
va
nt
hoff
plot
use
equat
dh
enthalpi
chang
r
ga
constant
ds
entropi
chang
absolut
temperatur
entropi
chang
obtain
equat
assay
done
differ
temperatur
calcul
variou
k
pyridin
deriv
papain
model
enzym
disk
diffus
method
use
preliminari
antibacteri
evalu
pyridin
deriv
mic
deriv
show
inhibit
preliminari
test
determin
microtitr
plate
techniqu
use
micro
dilut
method
brief
bacteri
strain
aureu
p
vulgari
group
streptococci
bacillu
sp
e
coli
p
aeruginosa
morganii
grown
dilut
colonyform
unit
cfu
ml
sodium
phosphat
buffer
spb
contain
luriabertani
lb
broth
synthes
deriv
dissolv
dmso
serial
dilut
perform
ml
lb
medium
microtitr
plate
achiev
requir
concentr
mgml
bacteri
inoculum
cfu
per
well
dmso
taken
neg
control
ceftriaxon
clotrimazol
taken
posit
control
incub
overnight
mic
taken
lowest
inhibitor
concentr
bacteri
growth
inhibit
averag
three
valu
calcul
mic
test
materi
bacteri
strain
agar
plate
count
method
ml
aliquot
bacteria
cfuml
spb
contain
lb
broth
incub
ml
dilut
compound
h
mixtur
bacteria
compound
serial
dilut
spb
plate
lb
plate
incub
overnight
bacteri
coloni
enumer
follow
day
determin
mic
bacteri
strain
well
microtitr
plate
visibl
bacteri
growth
remov
serial
sub
cultiv
ml
anoth
new
microtitr
plate
contain
ml
broth
per
well
incub
h
lowest
concentr
visibl
growth
defin
mbc
indic
kill
origin
inoculum
absorb
well
measur
wavelength
nm
micropl
manag
biorad
laboratori
compar
blank
solvent
dmso
use
neg
control
three
replic
done
compound
experi
repeat
two
time
bacteria
use
cystein
proteas
pathogenec
could
depict
structur
cif
homolog
burkholderia
pseudomallei
chbp
reveal
papainlik
fold
conserv
cyshisgln
catalyt
triad
proven
bacteri
pathogen
uniqu
papainlik
hydrolyt
activ
block
normal
host
cell
cycl
progress
core
avirul
avr
protein
avrpphb
plant
pathogen
pseudomona
syringa
resembl
papainlik
cystein
proteas
similar
avrpphb
protein
papain
includ
catalyt
triad
avrpphb
activ
site
turk
et
al
propos
basi
kinet
structur
studi
papain
seven
subsit
activ
site
five
subsit
import
bind
amino
acid
residu
substrat
varieti
intermedi
gener
papain
react
substrat
inhibitor
like
serin
proteas
cystein
proteas
tend
rel
shallow
solventexpos
activ
site
accommod
short
substrateinhibitor
segment
protein
loop
eg
endogen
inhibitor
cystatin
strand
inhibitor
tabl
name
structur
k
pyridylimidazo
pyridin
deriv
cystein
proteas
papain
type
inhibit
ki
mm
ic
mm
noncompetit
compound
bound
proteas
combin
hydrogen
bond
hydrophob
interact
part
investig
develop
novel
effici
cystein
proteas
inhibitor
ten
pyridylimidazo
pyridin
deriv
primarili
design
screen
basi
dock
energi
papain
elucid
possibl
mode
action
found
compound
specif
inhibitor
cystein
proteas
papain
nt
show
inhibit
type
proteas
like
serin
aspart
metalloproteas
specif
ca
clan
cystein
proteas
nt
show
signific
inhibit
clan
cystein
proteas
new
compound
devis
base
knowledg
abil
protein
alter
conform
accommod
bind
ligand
enabl
us
directli
compar
rel
posit
residu
bind
pocket
molecular
dock
studi
provid
structur
insight
bind
compound
figur
within
activ
site
papain
mainli
consist
catalyt
triad
cy
asp
moreov
role
residu
present
activ
site
papain
play
import
role
accommod
compound
also
reveal
initi
dock
perform
design
compound
papain
known
cystein
proteas
enzym
context
observ
interest
result
propos
inhibitor
take
advantag
aromat
hydrophil
residu
make
varieti
interact
target
enzym
although
compound
gave
signific
result
dock
papain
evalu
antibacteri
properti
wet
lab
experi
gave
insignific
result
data
shown
therefor
four
compound
consid
discuss
experi
like
kinet
thermodynam
studi
character
compound
potent
proinhibitor
perform
find
studi
shown
molecular
interact
compound
papain
similar
interact
observ
deriv
natur
occur
epoxid
inhibitor
figur
cystein
proteas
papain
especi
regard
hydrogen
bond
hydrophob
interact
ligand
conserv
residu
catalyt
bind
site
figur
ad
sever
papain
residu
particip
hydrophob
interact
compound
includ
pyridin
moieti
compound
interact
site
papain
includ
amino
acid
figur
ad
activ
site
residu
found
key
player
interact
compound
within
activ
site
mostli
hydrophob
interact
found
make
hydrogen
bond
compound
besid
mani
residu
also
found
activ
involv
tabl
furthermor
bind
energi
compound
papain
found
kcalmol
respect
great
agreement
wet
lab
experi
shall
discuss
later
tabl
confirm
accuraci
dock
protocol
sinc
bind
energi
direct
measur
strength
interact
compound
show
stronger
bind
within
activ
site
papain
comparison
inhibitor
dg
kcalmol
therefor
result
suggest
pyridylimidazo
pyridin
deriv
could
potent
inhibitor
papain
like
cystein
proteas
silico
interact
compound
papain
observ
discuss
valid
wet
lab
tabl
predict
antibacteri
compound
drug
http
wwworganicchemistryorg
tabl
interestingli
observ
silico
bind
energi
compound
papain
found
great
agreement
standard
error
kcalmol
valu
free
energi
bind
dg
observ
thermodynam
studi
tabl
similarli
enthalpi
chang
dh
bind
neg
wherea
entropi
ds
chang
bind
posit
indic
exotherm
entrop
driven
natur
bind
pattern
temperatur
depend
characterist
hydrophob
interact
discuss
earlier
compound
found
interact
activ
site
residu
papain
hydrophob
interact
instanc
silico
studi
observ
analysi
va
nt
hoff
plot
propos
inhibitor
three
differ
temperatur
wet
lab
experi
figur
prove
import
type
interact
posit
compound
within
activ
site
henc
thermodynam
well
silico
studi
reveal
hydrophob
interact
favor
bind
propos
inhibitor
papain
like
cystein
proteas
wet
lab
result
propos
non
competit
interact
compound
papain
except
compound
show
competit
interact
sum
result
molecular
dock
studi
thermodynam
analysi
compound
papain
show
compound
potenti
novel
uniqu
cystein
proteas
inhibitor
current
studi
cystein
proteas
inhibitori
activ
synthes
deriv
pyridylimidazo
pyridin
also
perform
papain
inhibit
constant
k
said
enzym
observ
mm
compound
respect
tabl
furthermor
calcul
ic
valu
also
found
mm
compound
respect
tabl
except
compound
rest
compound
show
non
competit
revers
inhibit
compound
irrespect
type
bind
show
hydrophob
entrop
driven
interact
deriv
eventu
evalu
antibacteri
activ
seven
clinic
import
microb
aureu
p
vulgari
group
streptococci
bacillu
sp
e
coli
p
aeruginosa
morganii
show
data
four
compound
signific
result
tabl
compound
strictli
follow
pattern
antiproteas
activ
toward
bacteri
growth
except
p
vulgari
e
coli
one
instanc
tabl
sinc
compound
much
differ
valu
mm
mm
cystein
proteas
papain
henc
antibacteri
activ
instanc
except
one
might
random
due
close
valu
compound
much
differ
valu
mm
mm
show
exact
pattern
antibacteri
activ
microb
except
e
coli
one
instanc
although
e
coli
contain
six
major
cystein
proteas
none
belong
ca
clan
papain
argu
compound
also
inhibit
cystein
proteas
clan
papain
low
efficaci
sinc
pyridylimidazo
pyridin
deriv
absolut
new
scaffold
toward
antibacteri
agent
henc
standard
compound
scaffold
avail
refer
clotrimazol
diphenyl
methyl
imidazol
deriv
ceftriaxon
thirdgener
cephalosporin
antibiot
broad
spectrum
activ
gramposit
gramneg
bacteria
use
posit
control
wherea
dmso
use
neg
control
mention
bacteri
speci
shown
secret
certain
cystein
proteas
play
import
role
pathogenec
differ
diseas
caus
microorgan
minimum
inhibitori
concentr
mic
compound
tabl
test
bacteria
except
e
coli
p
vulgari
observ
great
agreement
respect
inhibit
constant
k
ic
valu
papain
tabl
clearli
indic
compound
potenti
inhibit
papain
like
cystein
proteas
pathogen
partit
coeffici
logp
wellestablish
measur
compound
lipophil
distribut
calcul
logp
clogp
valu
major
drug
market
rang
zero
five
compound
studi
except
show
good
agreement
criteria
laid
predict
compound
potenti
drug
tabl
compound
show
threat
toxic
risk
assess
except
compound
show
threat
tumorogen
effect
due
presenc
isobutyl
group
among
test
compound
compound
potent
whose
mic
lowest
among
test
compound
show
maximum
drug
score
posit
valu
drug
like
summari
result
present
studi
establish
pyridylimidazo
pyridin
deriv
could
candid
novel
potent
inhibitor
papain
like
cystein
proteas
play
deleteri
role
progress
differ
diseas
caus
divers
microorgan
therefor
group
compound
could
subject
futur
research
confront
challeng
resist
microorgan
major
threat
global
file
type
inhibit
ki
compound
doc
